What is BioCryst Pharmaceuticals's revenue?

BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.

Is BioCryst Pharmaceuticals profitable?

BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.

What are BioCryst Pharmaceuticals's profit margins?

Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.

What is BioCryst Pharmaceuticals's earnings per share?

BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.

Where does BioCryst Pharmaceuticals's income statement data come from?

Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BioCryst Pharmaceuticals BCRX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$885.72M+1.2%	$874.84M+45.9%	$599.82M+7.6%	$557.51M+10.7%	$503.49M+11.7%
Total cost of revenue	$19.88M+4.2%	$19.08M+21.9%	$15.65M-6.1%	$16.67M+7.1%	$15.57M+26.9%
Gross profit	$865.83M+1.2%	$855.76M+46.5%	$584.17M+8.0%	$540.84M+10.8%	$487.91M+11.3%
Gross margin	97.8%-0.1pp	97.8%+0.4pp	97.4%+0.4pp	97%+0.1pp	96.9%-0.4pp
Research and development	$189.18M+13.9%	$166.13M-4.9%	$174.7M+2.1%	$171.18M+3.5%	$165.42M-5.3%
Selling, general and administrative	$360.73M+3.5%	$348.65M+4.6%	$333.37M+5.7%	$315.46M+9.0%	$289.33M+8.6%
Compensation and benefits	$79.73M-6.3%	$85.07M+3.0%	$82.61M+1.7%	$81.26M+11.1%	$73.13M+11.8%
Occupancy and equipment	$2.17M+8.1%	$2.01M-6.9%	$2.16M-2.0%	$2.2M-2.5%	$2.26M-2.0%
Impairment charges	——	$0—	$0—	$0—	$0—
Other operating expenses	——	——	——	——	——
Total costs & expenses	$1.27B+137%	$533.85M+1.9%	$523.72M+4.1%	$503.31M+7.0%	$470.31M+3.8%
Operating income	-$381.84M-212%	$340.99M+348%	$76.1M+40.4%	$54.2M+63.4%	$33.17M+1,404%
Operating margin	-43.1%-82.1pp	39%+26.3pp	12.7%+3.0pp	9.7%+3.1pp	6.6%+7.2pp
Interest expense	$75.16M-4.7%	$78.87M-11.6%	$89.19M-5.5%	$94.35M-3.2%	$97.5M-1.0%
Interest income	$9.9M-7.2%	$10.67M-6.0%	$11.35M-10.7%	$12.7M-7.6%	$13.74M-6.8%
Other income (expense), net	-$72.34M+1.7%	-$73.6M+11.0%	-$82.71M+4.3%	-$86.39M-2.4%	-$84.35M+0.1%
Income before income taxes	-$454.18M-270%	$267.39M+4,141%	-$6.62M+79.4%	-$32.19M+37.1%	-$51.18M+41.1%
Income tax expense	$3.81M+7.9%	$3.53M+63.3%	$2.16M-38.5%	$3.52M+53.7%	$2.29M+18.7%
Net income	-$457.98M-274%	$263.86M+3,106%	-$8.78M+75.4%	-$35.71M+33.2%	-$53.47M+39.8%
Net margin	-51.7%-81.9pp	30.2%+31.6pp	-1.5%+4.9pp	-6.4%+4.2pp	-10.6%+9.1pp
Diluted earnings per share	-$1.77-246%	$1.21+2,520%	-$0.05+72.2%	-$0.18+30.8%	-$0.26+39.5%
Basic earnings per share	-$1.73-238%	$1.25+2,600%	-$0.05+72.2%	-$0.18+30.8%	-$0.26+39.5%
Weighted-average shares, diluted	900.6M+3.1%	873.6M+1.4%	861.7M+1.5%	848.7M+1.6%	835.3M+1.1%
Weighted-average shares, basic	871.8M+4.0%	838.5M+0.4%	835.3M+0.4%	832M+0.4%	828.9M+0.3%
Acquired in-process research and development	——	——	——	——	——
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	——	——	——	——	——
Reclassification of equity awards to share-based liability	——	-$2.56M—	——	——	——
Remeasurement of share-based liability	$900.5K-56.1%	$2.05M—	——	——	——
Share-based compensation expense related to employee stock plans	$79.8M-6.3%	$85.14M+3.0%	$82.66M+1.7%	$81.26M+11.1%	$73.13M+11.8%
Amortization Of Debt Issuance Costs on Term Loans	——	——	——	——	——
Amortization of capitalized software and acquired intangible assets	——	——	——	——	——
Amortization of premium (discount) on investments, net	-$2.7M+37.7%	-$4.33M+27.8%	-$6M+18.2%	-$7.33M+24.2%	-$9.68M+15.7%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Capital investments accrued but not yet paid	——	——	——	$1.07M—	$0—
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$459.48M-275%	$262.98M+2,748%	-$9.93M+71.3%	-$34.62M+34.8%	-$53.11M+40.5%
Federal	——	$0—	$0—	$0—	$0—
Foreign	——	$1.24M+1.6%	$1.22M+1.6%	$1.2M+1.6%	$1.18M+1.7%
Current State And Local Tax Expense Benefit	——	$3.5M+20.5%	$2.91M+25.8%	$2.31M+34.8%	$1.71M+53.3%
Federal	——	$0—	$0—	$0—	$0—
Deferred Foreign Income Tax Expense Benefit	——	-$1.03M-16.9%	-$879.25K-20.4%	-$730.5K-25.6%	-$581.75K-34.4%
Deferred taxes	——	-$1.21M-21.5%	-$997.5K-27.4%	-$783K-37.7%	-$568.5K-60.6%
State	——	-$184K-55.6%	-$118.25K-125%	-$52.5K-496%	$13.25K-83.2%
Defined contribution plan costs	——	$5.76M-1.2%	$5.83M-1.1%	$5.9M-1.1%	$5.96M-1.1%
Depreciation	——	——	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	$1.36M+1,036%	-$145K+84.5%
Effective tax rates	——	$0.01+300%	$0+150%	-$0+60.0%	-$0.01+37.5%
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Other	——	$0+100%	-$0+50.0%	-$0.01+33.3%	-$0.01+25.0%
Sale of European ORLADEYO business	——	$3.87M+33.3%	$2.9M+50.0%	$1.93M+100%	$966.75K—
Sale of European ORLADEYO business	——	——	——	——	——
Share-based compensation	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Changes in unrecognized tax benefits	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Amount	——	-$3.57M-8.0%	-$3.31M-8.7%	-$3.04M-9.5%	-$2.78M-10.5%
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Percent	——	——	——	——	——
Equity modification associated with sale of BioCryst Ireland	——	$17.55M+33.3%	$13.16M+50.0%	$8.77M+100%	$4.39M—
Fair Value Adjustment, Share-Based Liability	——	——	——	——	$0—
Remeasurement of share-based liability	——	——	——	——	——
Options exercised	——	——	——	——	——
Finance Lease Interest Payment On Liability	$310K-8.8%	$340K-3.7%	$353K+0.9%	$350K+5.1%	$333K+5.4%
Finance Lease Principal Payments	$1.82M-8.6%	$1.99M+3.5%	$1.92M-2.2%	$1.96M+7.3%	$1.83M+7.4%
Finance Lease Right Of Use Asset Amortization	$1.94M-7.7%	$2.1M-1.3%	$2.13M+4.5%	$2.04M+7.3%	$1.9M+7.4%
Financing Lease, Expense	$2.25M-7.8%	$2.44M-1.7%	$2.48M+4.0%	$2.39M+7.0%	$2.23M+7.1%
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	-$378K-149%	-$152K+75.9%	-$631K-11.1%	-$568K+3.6%	-$589K+8.1%
Gain on sale of business and assets	——	$3.57M+33.3%	$2.67M+50.0%	$1.78M+100%	$891.5K—
Income Loss From Continuing Operations Before Income Taxes Domestic	——	$172.64M+51.6%	$113.85M+107%	$55.06M+1,577%	-$3.73M+94.0%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	$94.75M+45.9%	$64.96M+84.8%	$35.16M+556%	$5.36M+122%
Federal taxes	——	$0—	$0—	$0—	$0—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	-$52.45M-41.1%	-$37.17M-69.9%	-$21.88M-232%	-$6.59M-176%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	$56.15M+49.5%	$37.55M+98.2%	$18.95M+5,424%	$343K+102%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$1.29M+8.1%	$1.19M+8.8%	$1.09M+9.7%	$995.5K+10.7%
Share-based compensation	——	$4.84M+11.9%	$4.32M+13.5%	$3.81M+15.6%	$3.29M+18.5%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$4.93M+34.3%	$3.67M+52.2%	$2.41M+109%	$1.15M+1,176%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$2.57M+18.6%	$2.17M+22.9%	$1.76M+29.7%	$1.36M+42.3%
Changes in unrecognized tax benefits	——	-$217K-191%	-$74.5K-210%	$68K-67.7%	$210.5K-40.4%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$1.32M-7.7%	$1.43M-7.1%	$1.54M-6.7%	$1.65M-6.3%
Income Taxes Paid, Net	——	——	——	——	$1.2M-24.9%
Accounts payable	$30M-48.1%	$57.8M+34.9%	$42.84M—	——	——
Increase (decrease) in contract liabilities and current deferred income	——	——	——	——	$0—
Increase (Decrease) in Inventories	$5.62M+243%	$1.64M-50.1%	$3.29M+5.5%	$3.12M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	$4.16M-46.8%	$7.83M+47.2%	$5.32M—	——	——
Increase Decrease In Receivables	$23.29M-36.7%	$36.81M+28.7%	$28.61M-10.3%	$31.91M-2.9%	$32.85M+44.7%
Decrease in royalty financing obligations	$74.51M+8.9%	$68.43M-12.4%	$78.09M-3.6%	$81.01M—	——
Shares issuable under the employee stock purchase plan	76K-18.3%	93K+25.7%	74K+45.1%	51K+200%	17K—
Effect of equity units (in shares)	12.5M-13.6%	14.4M+36.0%	10.6M+78.6%	5.9M+203%	2M—
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	$15.78M+46.7%	$10.76M+145%	$4.4M—
Interest income and other, net	$9.9M-7.2%	$10.67M-6.0%	$11.35M-10.7%	$12.7M-7.6%	$13.74M-6.8%
Interest Paid, Excluding Capitalized Interest, Operating Activity	$20.67M-12.9%	$23.74M-27.9%	$32.93M-11.1%	$37.02M+7.2%	$34.55M+13.7%
Interest paid, royalty financing obligations	$62.35M-8.9%	$68.43M-12.4%	$78.09M-3.6%	$81.01M+6.5%	$76.09M-1.4%
Inventory Write Down	$921K-12.8%	$1.06M0.0%	$1.06M-55.7%	$2.39M+52.0%	$1.57M+15.4%
Loss on lease termination	——	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$62.09M+118%	-$349.93M-157%	-$135.99M—	——	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$309.44M-2,160%	-$13.69M-116%	$87.59M+6.2%	$82.51M+54.6%	$53.38M-3.0%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$313.1M-9.9%	$347.37M+592%	$50.2M—	——	——
Non-cash interest expense on royalty financing obligations	$52.94M-0.4%	$53.16M-0.3%	$53.34M-2.0%	$54.44M-1.6%	$55.3M-1.2%
Number of operating segments	——	——	——	——	1.8+75.0%
Number of reportable segments	——	——	——	——	1.8+75.0%
Occupancy and Related Charges	$2.17M+8.1%	$2.01M-6.9%	$2.16M-2.0%	$2.2M-2.5%	$2.26M-2.0%
Operating Lease Payments	$1.49M+1.4%	$1.47M-17.3%	$1.77M-10.3%	$1.98M-2.0%	$2.02M-6.5%
Foreign currency translation	-$1.1M-63.5%	-$674K-68.1%	-$401K-159%	$685K+536%	-$157K+79.8%
Unrealized gains (losses) on available-for-sale securities	——	——	——	——	——
Other comprehensive income/(loss)	-$1.5M-69.9%	-$883K+23.4%	-$1.15M-206%	$1.09M+202%	$361K+187%
Other income, net (Note 6)	——	——	——	——	——
Payment Of Royalty Release Fees	——	$15.5M+33.3%	$11.63M+50.0%	$7.75M+100%	$3.88M—
Payments for Restructuring	$6.35M+659%	$836K+32.1%	$633K-11.5%	$715K-57.6%	$1.69M-63.7%
Payments of Debt Issuance Costs	——	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$8.68M-1.9%	$8.85M+49.2%	$5.93M+6.6%	$5.56M-14.9%	$6.54M-13.3%
Payments to Acquire Debt Securities, Available-for-Sale	$213.48M-18.6%	$262.24M+48.8%	$176.27M+21.9%	$144.56M-36.5%	$227.52M-14.7%
Payments to Acquire Businesses, Net of Cash Acquired	——	——	——	——	——
Payments to Acquire Productive Assets	$2.73M+10.5%	$2.47M+5.4%	$2.34M+122%	$1.06M+2.3%	$1.03M-8.2%
Divestiture of businesses, net of cash transferred	——	-$6.18M-33.3%	-$4.64M-50.0%	-$3.09M-100%	-$1.55M—
Debt issued (Note 13)	——	——	——	——	——
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$26.2M+187%	$9.12M—	——	——	——
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$401.88M+56.6%	$256.65M-3.4%	$265.65M+16.4%	$228.13M-18.4%	$279.48M-12.8%
Common stock issued to directors in lieu of cash retainer	——	——	——	——	——
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$0—	$0—	$0—	$0—	$0—
Repayment Of Royalty Financing Liabilities, Principal	$23.36M+2.1%	$22.88M+39.5%	$16.41M+315%	$3.96M—	——
Right Of Use Asset Obtained In Exchange For Finance Lease Liability	$191K-78.0%	$870K-39.3%	$1.43M-31.1%	$2.08M+5.7%	$1.97M+41.4%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability	$4.45M+1,116%	$366K-32.6%	$543K-3.4%	$562K+41.6%	$397K-9.4%
Royalty revenues payable	——	——	——	——	-$84.95M-15.1%
Settlement of share-based liability	——	——	——	——	——
Stock-based compensation	$79.73M-6.3%	$85.07M+3.0%	$82.61M+1.7%	$81.26M+11.1%	$73.13M+11.8%
Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost	——	——	——	——	——
Total stock-based compensation expense included in “Total costs and expenses”	$79.8M-6.3%	$85.14M+3.0%	$82.66M+1.7%	$81.26M—	——
Stock Issued During Period Value Acquisitions	——	——	——	——	——
Stock issued for employee stock purchase plan	——	——	——	——	——
Exercise of warrants	——	——	——	——	——
Stock Issued During Period Value Issued For Services	$86K+45.8%	$59K+43.9%	$41K+57.7%	$26K-10.3%	$29K-14.7%
Restricted stock acquisition consideration	$0—	$0—	$0—	$0—	$0—
Stock Issued During Period, Value, Stock Options Exercised	$25.02M+218%	$7.88M+24.7%	$6.32M+3.3%	$6.11M+107%	$2.96M+29.7%
Tangible Asset Impairment Charges	——	$0—	$0—	$0—	$0—
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions	——	$603K+33.3%	$452.25K+50.0%	$301.5K+100%	$150.75K—
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	——	$386K+2.2%	$377.75K+2.2%	$369.5K+2.3%	$361.25K+2.3%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	-$68.22M-41.4%	-$48.26M-70.6%	-$28.29M-240%	-$8.32M-171%
Add: dilutive effect of potential common shares (in shares)	——	——	$26.46M+58.0%	$16.75M+163%	$6.38M—
Taxes withheld on stock-based awards included in accrued expenses	——	——	——	$912K—	——
EBIT	-$381.84M-212%	$340.99M+348%	$76.1M+40.4%	$54.2M+63.4%	$33.17M+1,404%
EBITDA	-$379.72M-211%	$342.38M+342%	$77.4M+39.5%	$55.48M+61.1%	$34.44M+2,756%
EBITDA	-$379.72M-211%	$342.38M+342%	$77.4M+39.5%	$55.48M+61.1%	$34.44M+2,756%
EBITDA margin	-42.9%-82.0pp	39.1%+26.2pp	12.9%+3.0pp	10%+3.1pp	6.8%+7.1pp
EBIT	-$381.84M-212%	$340.99M+348%	$76.1M+40.4%	$54.2M+63.4%	$33.17M+1,404%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BioCryst Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's revenue?: BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
Is BioCryst Pharmaceuticals profitable?: BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
What are BioCryst Pharmaceuticals's profit margins?: Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
What is BioCryst Pharmaceuticals's earnings per share?: BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
Where does BioCryst Pharmaceuticals's income statement data come from?: Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.